CL2021003202A1 - Compuestos de pirrolidina - Google Patents
Compuestos de pirrolidinaInfo
- Publication number
- CL2021003202A1 CL2021003202A1 CL2021003202A CL2021003202A CL2021003202A1 CL 2021003202 A1 CL2021003202 A1 CL 2021003202A1 CL 2021003202 A CL2021003202 A CL 2021003202A CL 2021003202 A CL2021003202 A CL 2021003202A CL 2021003202 A1 CL2021003202 A1 CL 2021003202A1
- Authority
- CL
- Chile
- Prior art keywords
- formula
- compounds
- pyrrolidine compounds
- nhso2nh
- ch2nhch2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención proporciona compuestos de la Fórmula (I) en donde L se selecciona del grupo que consiste en -CH2NHCH2-, - CH2NH-, -NH-, -S-, -S(O)-, -S(O)2-, -O-, -OCH2-, -OCH2CH2O-, - NHSO2NH- (II), y (III) o una sal farmacéuticamente aceptable de estos; un compuesto de la fórmula (IV), procesos para preparar los compuestos y sus sales, una composición farmacéutica y métodos para tratar pacientes que necesiten dicho tratamiento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382477 | 2019-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021003202A1 true CL2021003202A1 (es) | 2022-09-09 |
Family
ID=66821161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021003202A CL2021003202A1 (es) | 2019-06-07 | 2021-12-01 | Compuestos de pirrolidina |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11286249B2 (es) |
| EP (1) | EP3980409A1 (es) |
| JP (4) | JP6940717B2 (es) |
| KR (3) | KR102629923B1 (es) |
| CN (1) | CN114008021B (es) |
| AU (1) | AU2020287599B2 (es) |
| BR (1) | BR112021023347A2 (es) |
| CL (1) | CL2021003202A1 (es) |
| CO (1) | CO2021016295A2 (es) |
| CR (1) | CR20210602A (es) |
| DO (1) | DOP2021000254A (es) |
| EA (1) | EA202193007A1 (es) |
| EC (1) | ECSP21088515A (es) |
| IL (2) | IL321703B1 (es) |
| JO (1) | JOP20210319B1 (es) |
| MA (1) | MA56115A (es) |
| MX (2) | MX2021014913A (es) |
| MY (1) | MY200810A (es) |
| PE (1) | PE20220134A1 (es) |
| PH (1) | PH12021553062A1 (es) |
| SA (1) | SA521431048B1 (es) |
| SG (1) | SG11202113244UA (es) |
| UA (1) | UA128540C2 (es) |
| WO (1) | WO2020247429A1 (es) |
| ZA (1) | ZA202109251B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3235992A1 (en) | 2021-11-03 | 2023-05-11 | Liang Tan | Substituted phenylpropionic acid derivative and use thereof |
| CA3248327A1 (en) | 2022-01-26 | 2023-08-03 | Eli Lilly And Company | PYRROLIDINE COMPOUNDS |
| EP4692073A1 (en) | 2023-03-24 | 2026-02-11 | Shanghai Jingxin Biomedical Co., Ltd. | Cyclic amine derivative, and composition and use thereof |
| WO2024217537A1 (zh) * | 2023-04-21 | 2024-10-24 | 深圳信立泰药业股份有限公司 | 一种叔胺类化合物及其制备方法和医药用途 |
| EP4711355A1 (en) | 2023-05-11 | 2026-03-18 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystal form of lipoprotein compound and preparation method therefor |
| TW202509024A (zh) | 2023-05-19 | 2025-03-01 | 大陸商深圳信立泰藥業股份有限公司 | 一種磺醯胺類化合物及其製備方法和醫藥用途 |
| EP4734986A1 (en) | 2023-06-30 | 2026-05-06 | Eli Lilly and Company | Therapeutic uses and doses of lp(a) disrupter compounds |
| KR20260041100A (ko) | 2023-07-21 | 2026-03-26 | 일라이 릴리 앤드 캄파니 | Lp(a) 저하 활성을 갖는 피페리딘, 모르폴린 및 테트라히드로-피리다진 화합물 |
| KR20260041097A (ko) | 2023-07-21 | 2026-03-26 | 일라이 릴리 앤드 캄파니 | Lp(a) 저하 활성을 갖는 피롤리딘 화합물 |
| AU2024298640A1 (en) | 2023-07-21 | 2026-01-22 | Eli Lilly And Company | Piperidine Compounds with Lp(a) Lowering Activity |
| WO2025024218A1 (en) | 2023-07-21 | 2025-01-30 | Eli Lilly And Company | PYRROLIDINE COMPOUNDS WITH Lp(a) LOWERING ACTIVITY |
| CN119490445A (zh) * | 2023-08-15 | 2025-02-21 | 深圳信立泰药业股份有限公司 | 一种酰基类化合物及其制备方法和医药用途 |
| TW202523293A (zh) * | 2023-11-17 | 2025-06-16 | 大陸商上海翊石醫藥科技有限公司 | 一種取代的２－（吡咯烷－３－基）乙酸的衍生物及其製備方法和用途 |
| WO2025108255A1 (zh) * | 2023-11-20 | 2025-05-30 | 上海齐鲁制药研究中心有限公司 | 一种多环类衍生物、其制备方法和应用 |
| WO2025237188A1 (zh) * | 2024-05-14 | 2025-11-20 | 石家庄以岭药业股份有限公司 | 一种LP(a)抑制剂化合物及其应用 |
| WO2025255324A1 (en) * | 2024-06-06 | 2025-12-11 | Lapis Therapeutics, Inc. | Inhibitors of lipoprotein(a) assembly |
| WO2026061518A1 (zh) * | 2024-09-23 | 2026-03-26 | 上海京新生物医药有限公司 | 一种环状胺衍生物的固体形式、制备方法及药物组合物 |
| JP7850336B1 (ja) * | 2024-11-14 | 2026-04-22 | イーライ リリー アンド カンパニー | Ｌｐ（ａ）阻害剤化合物を含む経口組成物 |
| CN121609698A (zh) * | 2026-01-30 | 2026-03-06 | 山东京新药业有限公司 | 一种莫伐培林及中间体的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2685325B1 (fr) * | 1991-12-20 | 1994-02-04 | Adir Cie | Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| EP1452521A4 (en) * | 2001-08-17 | 2007-03-14 | Eisai R&D Man Co Ltd | CYCLIC COMPOUND AND AGONIST OF PPAR RECEPTOR |
| AU2003300438A1 (en) | 2003-12-24 | 2005-08-03 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
| WO2005068412A1 (en) | 2003-12-24 | 2005-07-28 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| CN101765587A (zh) * | 2007-07-27 | 2010-06-30 | 弗·哈夫曼-拉罗切有限公司 | 作为taar配体的2-氮杂环丁烷甲胺类和2-吡咯烷甲胺类 |
| AU2017215697A1 (en) * | 2016-02-03 | 2018-07-05 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | N-sulfonyl benzamide derivative with heterocyclic substituent, preparation method therefor and pharmaceutical application thereof |
| CN112321475B (zh) | 2020-11-13 | 2022-06-10 | 四川大学 | 一种γ-氨基酸类似物及其合成方法 |
-
2020
- 2020-06-03 MA MA056115A patent/MA56115A/fr unknown
- 2020-06-03 KR KR1020227043106A patent/KR102629923B1/ko active Active
- 2020-06-03 US US17/056,144 patent/US11286249B2/en active Active
- 2020-06-03 PH PH1/2021/553062A patent/PH12021553062A1/en unknown
- 2020-06-03 CR CR20210602A patent/CR20210602A/es unknown
- 2020-06-03 MY MYPI2021007256A patent/MY200810A/en unknown
- 2020-06-03 IL IL321703A patent/IL321703B1/en unknown
- 2020-06-03 EA EA202193007A patent/EA202193007A1/ru unknown
- 2020-06-03 KR KR1020217040065A patent/KR102477481B1/ko active Active
- 2020-06-03 PE PE2021002037A patent/PE20220134A1/es unknown
- 2020-06-03 IL IL288174A patent/IL288174B2/en unknown
- 2020-06-03 EP EP20747210.1A patent/EP3980409A1/en active Pending
- 2020-06-03 KR KR1020247002433A patent/KR102720992B1/ko active Active
- 2020-06-03 UA UAA202106553A patent/UA128540C2/uk unknown
- 2020-06-03 BR BR112021023347A patent/BR112021023347A2/pt unknown
- 2020-06-03 AU AU2020287599A patent/AU2020287599B2/en active Active
- 2020-06-03 MX MX2021014913A patent/MX2021014913A/es unknown
- 2020-06-03 CN CN202080041924.XA patent/CN114008021B/zh active Active
- 2020-06-03 WO PCT/US2020/035825 patent/WO2020247429A1/en not_active Ceased
- 2020-06-03 JP JP2021505713A patent/JP6940717B2/ja active Active
- 2020-06-03 SG SG11202113244UA patent/SG11202113244UA/en unknown
-
2021
- 2021-09-02 JP JP2021143227A patent/JP7508422B2/ja active Active
- 2021-11-18 ZA ZA2021/09251A patent/ZA202109251B/en unknown
- 2021-11-30 CO CONC2021/0016295A patent/CO2021016295A2/es unknown
- 2021-12-01 CL CL2021003202A patent/CL2021003202A1/es unknown
- 2021-12-01 JO JOJO/P/2021/0319A patent/JOP20210319B1/ar active
- 2021-12-03 MX MX2025001789A patent/MX2025001789A/es unknown
- 2021-12-07 DO DO2021000254A patent/DOP2021000254A/es unknown
- 2021-12-07 SA SA521431048A patent/SA521431048B1/ar unknown
- 2021-12-07 EC ECSENADI202188515A patent/ECSP21088515A/es unknown
-
2022
- 2022-02-15 US US17/671,806 patent/US12441714B2/en active Active
-
2024
- 2024-06-18 JP JP2024098153A patent/JP7658014B2/ja active Active
-
2025
- 2025-03-26 JP JP2025052039A patent/JP2025098178A/ja active Pending
- 2025-07-11 US US19/267,125 patent/US20260055086A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000254A (es) | Compuestos de pirrolidina | |
| PY2240956A (es) | Nuevos Compuestos bicíclicos y sus usos | |
| UY40470A (es) | Compuestos tricíclicos y sus usos | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| CR20190124A (es) | Inhibidores de ssao de aminopirimidina | |
| AR126251A1 (es) | Inhibidores de cdk2 | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| DOP2024000039A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| EA202192433A1 (ru) | Соединения, полезные в терапии вич | |
| AR128500A1 (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| CO2021014210A2 (es) | Compuestos de pirrol | |
| CO2021017202A2 (es) | Compuestos tricíclicos | |
| AR124449A1 (es) | Inhibidores de sos1 y usos de los mismos | |
| CL2025000445A1 (es) | Inhibidores de kif18a y usos de estos | |
| CL2023002486A1 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| CO2025004701A2 (es) | Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina | |
| MX2019004842A (es) | Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc. | |
| CO2024012770A2 (es) | Inhibidores de proteínas de unión a emopamilo y usos de estos | |
| MX2019003585A (es) | Derivados de tetrahidropiridina y su uso como agentes antibacterianos. | |
| MX2024012198A (es) | Compuestos y metodos para tratar canceres | |
| CO2025005872A2 (es) | Compuestos tricíclicos y sus usos | |
| CO2025001460A2 (es) | Inhibidores de proteína de unión a emopamil y usos de estos | |
| AR128894A1 (es) | Inhibidores de kras | |
| AR117270A1 (es) | 3,3-difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que comprenden lo mismo | |
| BR112022011123A2 (pt) | Composto, processo para a preparação de um composto, usos de um composto, métodos para o tratamento de câncer e invenção |